CME: Pediatric Crohn’s disease: therapeutic updates and optimizing treatment
Cost: FreeView Offer chevron_right
Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that is defined by a transmural process that often occurs in the terminal ileum but may occur in any portion of the GI tract. Although the exact etiology of CD is unknown, a handful of genetic, immunological, and environmental risk factors have been identified. Research suggests that in genetically susceptible patients, there is an impaired immune response to commensal or pathogenic intestinal microbiota that drives mucosal inflammation. The incidence of pediatric CD (pCD) is increasing around the globe, varying between 2.5 to 11.4 per 100,000, with an estimated prevalence of 58 per 100,000. Approximately 25% of patients are diagnosed with IBD before the age of 18. Intestinal and abdominal complications such as strictures, abscesses, and fistulas are common among pediatric patients and increase as the disease progresses. IBD impairs attendance at school, and psychosocial ramifications in children diagnosed with IBD incdude a higher incidence of depression and anxiety.
By the end of the session the participant will be able to:
- Describe differences between European and American approaches to pCD
- Identify the present nutritional and pharmacotherapeutic treatment options currently available for management of pCD and apply them to patient cases using evidence-based medicine
- Identify new and emerging approaches to and therapies for the treatment of pCD
- Evaluate a treatment plan for a specific patient based on severity of pCD to optimize safety and efficacy, suggesting modifications for improvement
The following healthcare professionals: pediatricians and pediatric gastroenterologists; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who clinically encounter patients with pCD.